The potential of 1018 ISS adjuvant in hepatitis B vaccines
| Autor: | Rebecca Mulligan, Nitin Bhardwaj, Francisco Diaz-Mitoma, Nelson F. Eng |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cirrhosis
Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Immunology Virus Adjuvants Immunologic medicine Humans Immunology and Allergy Hepatitis B Vaccines Hepatitis B Antibodies Pharmacology business.industry Antibody titer Hepatitis B medicine.disease Virology Vaccination Chronic infection Clinical Trials Phase III as Topic Oligodeoxyribonucleotides Hepatocellular carcinoma Product History business Adjuvant |
| Zdroj: | Human Vaccines & Immunotherapeutics. 9:1661-1672 |
| ISSN: | 2164-554X 2164-5515 |
| Popis: | Hepatitis B (HBV) virus infects the liver, and upon chronic infection, can cause liver cirrhosis and hepatocellular carcinoma. Despite universal vaccination programs against the virus, HBV still affects over 2 billion people worldwide, with over 240 million developing a chronic infection. While current alum-adjuvanted vaccines have shown efficacy in promoting seroprotection in healthy adults, 5-10% of immune-competent populations fail to achieve long-lasting seroprotection from these formulations. Furthermore, a large proportion of immunocompromised patients fail to achieve seroprotective antibody titers after receiving these vaccines. A novel vaccine candidate, HEPLISAV™, uses immunostimulatory sequences (ISS), in its formulation that helps induce a robust humoral and cell mediated immunity against HBV. In Phase III clinical trials, HEPLISAV™ has been shown to elicit seroprotective antibody titers with fewer immunizations. Similar safety profiles are demonstrated when compared with current HBV vaccines. For these reasons, HEPLISAV™ is an attractive vaccine to combat this global disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|